In Italy, it was noted that fibromyalgia, like migraine, was The authors proposed that cannabinoid treatments would be indicated for in common with other causes of peripheral neuropathic pain. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and. Russo has proposed that the effectiveness of cannabinoid medicine in Migraines can cause dizziness, nausea, numbness or tingling in the.
Fibromyalgia Deficiency lead migraines to or Cannabinoids of can
And they often overlap, with patients presenting with some combination of the three quite often. Currently, several types of pharmaceuticals are used to treat migraines.
Pain relievers like ibuprofen, aspirin, caffeine, and acetaminophen may help mild migraines but regular use of these can cause problematic side effects that include bleeding stomach ulcers and new headaches caused by medication over-use.
Triptans like Imitrex are injectables that block blood vessels to the brain, aborting the onset of migraines if taken early enough.
Ergotamine combined with caffeine can be used if the migraine lasts more than 48 hours, but this combination can also exacerbate the nausea and vomiting that often occurs. Narcotics, steroids, and anti-nausea medicines are prescribed for persistent painful migraines. Pharmaceuticals are sometimes helpful in preventing migraine headaches.
Blood pressure medications, anti-depressants, anti-seizure medications, and Botox have all been used with varying rates of success. Some of these are quite effective, but each has its own set of possible side effects. For years cannabis was used to treat migraines; it was prescribed extensively in Western medicine between and Queen Victoria used it, and patients still use cannabis to prevent and treat migraine headaches. The trigeminovascular system see image below is considered by many to be at the root of migraine pathophysiology, both through neurons and blood vessels.
CB1 receptors are dense in the trigeminovascular system and research on endocannabinoids in these areas indicates an important role of the ECS in migraine episodes. The endocannabinoid anandamide inhibits the trigeminovascular system as part of its modulating functions, and analyzation of cerebrospinal fluid in chronic migraineurs revealed significantly lower levels of circulating anandamide in those patients.
Inflammation, serotonin, dopamine and depleted beta-endorphins in the central nervous system contribute to migraine syndromes, all of which are modulated by the ECS. All this lends credence to the link between migraines and dysfunction of the Endocannabinoid System. Anyone with fibromyalgia knows the frustration of diagnosing and treating this disabling condition. Fibromyalgia is the most common diagnosis in American rheumatology practices.
Over time, these painful areas intensify pain perception in the brain leading to disturbances in sleep, dysfunction of the nervous system, and depression. Unfortunately, the depression of fibromyalgia does not respond well to commonly used anti-depressant medication. The connection between hyperalgesia increased sensitivity to pain and the endocannabinoid system is supported by studies that injected cannabinoid antagonists into mice.
When the CB1 receptors were blocked this way, the mice experienced significant pain, which was relieved by the injection of synthetic cannabinoids.
This and other studies support the use and study of cannabinoid agonists for chronic pain conditions like fibromyalgia and migraines. Supplementing a deficient endocannabinoid system with phytocannabinoids could help patients with fibromyalgia regain some quality of life. They surveyed people with fibromyalgia and had them compare cannabis to the three medications currently approved by the FDA for their condition. Irritable Bowel Syndrome IBS is as debilitating as fibromyalgia and migraines, as evidenced by the numerous graphic advertisements seen regularly on TV with patients afraid to get very far from a bathroom.
It, like the other conditions discussed here, is a diagnosis of exclusion with no objective tissue or lab findings to rely upon. People with IBS have fluctuating symptoms of GI pain, spasms, distention, and bouts of diarrhea with occasional constipation. The unpredictable nature of these symptoms can be triggered by infection or changes in diet, which may explain the common correlation with anxiety.
It is the most common referral diagnosis for American gastroenterologists. Gastrointestinal propulsion, secretion and inflammation are all modulated by the ECS. In some cases I have even seen it disappear altogether, at least during the period of clinical monitoring. In the case of fibromyalgia, the findings of the research back the idea of a hypofunction of the ECS at the central level, with significantly reduced levels of AEA being found in the cerebrospinal fluid CSF of patients with this pathology 7.
As for irritable bowel syndrome, the ECS is well represented in the gastrointestinal tract, with receptors both in the surface and in the intestinal smooth muscle. To sum up, the most important functions of this system in the digestive apparatus can be said to be a reduction in gastric secretion, regulation of the lower oesophageal sphincter, reduction in motility of the digestive apparatus at all levels stomach, small intestine and colon , reduction in intestinal secretion and control of visceral sensitivity.
In addition, it has been shown that they act in situations involving intestinal inflammation and dysfunction. When one considers the symptoms of irritable bowel syndrome pain, spasm, digestive discomfort, altered bowel movements with diarrhoea or constipation or an alternation between the two, accompanied by anxiety , it is easy to see that this might be explained by a failure of the ECS.
Once again, in this pathology one sees a reduction in AEA, and as shown by a study in intestinal biopsies from IBS sufferers, an increase in TRPV1 receptor fibres, which might explain the hypersensitivity and pain. In all these pathologies, an improvement in the specific symptoms can be observed when treated with cannabinoid. The positive results are also reflected in an improvement in quality of life.
In any medical discussion of treatments, the more these treatments impact the process of disease production, the greater the anticipated effectiveness. These are what we call physio-pathological treatments and would be the case of cannabinoids. As more and more pathologies are confirmed involving a deficiency of the ECS and are added to the list of conditions that can be improved with such treatment, we can answer the sceptics who question the use of cannabinoids as a universal panacea by saying that they simply treat the existing failure.
We must again insist on the need, as well as scientific consensus, for randomised placebo-controlled clinical trials and also analytical and genetic studies. All the evidence appears to point to the real existence of CECD, and I have held this belief ever since, coming from the field of problematic drug use, I first began to get involved in the study and understanding of such diseases and the ECS.
For a clinical practitioner, this hypothesis is almost self-evident. It is rational and, in empirical terms, it matches the praxis almost perfectly. Indisputably, final confirmation requires more scientific evidence.
Such studies will also make it possible to raise conceptual differences, such as for example whether all such conditions correspond to defective ECS or whether some might involve definitive or transitory deregulations, and in which cases they are the primary cause and in which they are secondary failures resulting from other causes. In short, based on all the above, but also on the fact that there are other compounds as well as cannabinoids that might help to tackle these deficiencies, I would like to take this opportunity to make an observation and a proposal.
Medical specialities have never been named after the treatments they use. The speciality concerned with neurological diseases, for example is neurology; endocrinology is concerned with endocrines; cardiology with the cardiovascular system, and so on. And yet, in this field we talk about cannabis medicine. Uniquely, it is a field of medicine that is named after some of the products used in treatment. I would therefore like to formally propose that we stop referring to "cannabis medicine" and speak instead of endocannabinology , a speciality that is concerned with the study and treatment of alterations of the ECS.
Clinical endocannabinoid deficiency CECD: Cannabis and Cannabinoid Research. July , 1 1: Care and feeding of the endocannabinoid system: Abnormal degradation of endocannabinoids in migrainous women. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.
Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. The cannabis plant contains more than a hundred chemicals known as phytocannabinoids, each having Demyelinating diseases are medical conditions in which the principal pathogenic process targets The term 'refractory epilepsy' is used to describe cases in which epileptic fits are so frequent Skip to main content.
Failure in the Endocannabinoid System:
What is Clinical Endocannabinoid Deficiency?
Some emerging research indicates fibromyalgia, migraines and many brain disorders have been linked to neurotransmitter deficiencies. By using CBD-rich cannabis products, you can reap some of the medicinal benefits. Clinical endocannabinoid deficiency (CECD) has been studied in Cannabinoids and the ECS is what helps keep your entire body in homeostasis or balance. an ECS deficiency and medical conditions like migraines, fibromyalgia, to function at proper levels, an endocannabinoid deficiency can result. to Clinical Endocannabinoid Deficiency (CED) are migraines, fibromyalgia, may help mild migraines but regular use of these can cause problematic A survey of adults who used cannabis for migraine prophylaxis.